Kefurox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kefurox

Kefurox is a prescription-only medication whose active component is the semisynthetic compound Cefuroxime. It functions as a broad-spectrum antibiotic to stop the growth of and eliminate bacteria responsible for systemic bacterial infections.


Quick Facts

Property Description
Active ingredient Cefuroxime
Form Tablet, Suspension, Injection (Powder for solution)
Pharmacological class Second-generation cephalosporin (Antibiotic)
Common use Anti-infective agent for bacterial infections
Origin Semisynthetic

What Type of Antibiotic is Kefurox?

Kefurox is a second-generation cephalosporin belonging to the beta-Lactam antibiotic family, designated primarily as an anti-infective agent. This classification places Cefuroxime in a group that is clinically recognized for its expanded activity against certain bacteria. Crucially, the Cefuroxime structure provides enhanced stability against certain bacterial defense mechanisms, such as the production of beta-lactamase enzymes, a differentiating factor. This inherent stability often makes it a preferred choice in the initial management of common community-acquired bacterial illnesses.


Composition and Available Forms of Cefuroxime

The active ingredient, Cefuroxime, is prepared in two specific chemical variants to accommodate different administration needs: Cefuroxime sodium for injections and Cefuroxime axetil for oral use. As a single-ingredient product derived from a semisynthetic process, it is formulated into several pharmaceutical preparations, including a lyophilized powder for reconstitution into an injection solution (for parenteral administration) and an oral tablet or oral suspension suitable for general patient use. The distinct presence of the pro-drug Cefuroxime axetil is a key feature, making the drug highly adaptable for both hospital and outpatient settings.


How Kefurox Functions as a Bactericidal Agent

Kefurox exerts a powerful bactericidal (bacteria-killing) physiological action by directly interfering with the structural integrity of the bacterial cell. This mechanism involves the active inhibition of bacterial cell wall synthesis, which causes the microbial structure to fail. The general purpose of this potent disruption is to rapidly eliminate invading microorganisms, serving as a critical step in addressing and resolving the root cause of the bacterial infection. The primary role of this drug class is the elimination of susceptible bacteria.

Regulatory References

  1. WHO Essential Medicines

What side effects are possible with Kefurox?

Adverse Reaction Scope

Kefurox (cefuroxime) is a cephalosporin antibiotic associated with adverse reactions primarily involving the gastrointestinal, nervous, immune, and blood/lymphatic systems. The frequency classifications are based on regulatory standards.

Classification Examples of Adverse Reactions (System-Organ Class)
Common (1% to 10%) Diarrhea, loose stools, nausea, vomiting (Gastrointestinal); Headache, dizziness (Nervous System); Eosinophilia (Blood and Lymphatic System)
Uncommon (0.1% to 1%) Rash, pruritus (Skin); Abdominal cramps (Gastrointestinal)
Incidence Not Known Seizures, Encephalopathy (Nervous System); Anaphylaxis (Immune System); Severe Cutaneous Reactions (Skin)

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions documented in official sources include severe hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome) and Clostridioides difficile-associated diarrhea (CDAD), which can be life-threatening. Other clinically significant reactions include blood dyscrasias (neutropenia, hemolytic anemia) and seizures, particularly at higher doses or in patients with impaired kidney function.

Safety Restrictions and Limitations:

  • Hypersensitivity: The drug is contraindicated in patients with a known severe allergy to cephalosporins or other beta-lactam antibiotics due to cross-sensitivity risk.
  • Renal Impairment: Dosage adjustment is required in patients with significantly impaired kidney function to prevent drug accumulation and potential neurotoxicity.
  • Diagnostic Interference: The drug may cause a false-positive result in certain non-enzymatic urine glucose tests (use of glucose oxidase or hexokinase methods is recommended) and can cause a positive Direct Coombs’ test.
  • Pediatrics: Safety and efficacy have not been established in infants under 3 months of age.

High-Level Safety Summary

The overall safety profile is dominated by common, generally mild gastrointestinal effects, but it necessitates explicit warnings regarding rare but serious class-specific risks, such as CDAD and anaphylaxis, typical of beta-lactam antimicrobials. The regulatory texts emphasize the need for careful use in special populations, particularly those with compromised renal function or a history of colitis, and detail specific laboratory test interferences.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage involving cephalosporin antibiotics, such as Kefurox (Cefuroxime), is officially documented in regulatory information as potentially leading to effects within the central nervous system. The principal physiological manifestation reported is cerebral irritation, which can escalate to severe outcomes including convulsions (seizures). A specific consideration noted in official labeling is that the effects of the medicine may be increased in individuals with kidney disease due to the slower clearance of the drug from the body.


Immediate Actions and Management

In the event of a suspected overdosage, immediate medical attention must be sought. Official guidance mandates contacting a poison control center or emergency room at once. Urgent medical services must be called if the individual has collapsed, experienced a seizure, or cannot be awakened, as these are life-threatening signs. The regulatory documents confirm that no specific antidote is known for Cefuroxime. Management is defined as providing symptomatic and supportive treatment. Furthermore, documentation states that excessively high serum levels of the drug can be reduced by hemodialysis or peritoneal dialysis as procedural steps.

Therapeutic Uses of Kefurox

What Kefurox Treats: Main Uses and Benefits

Kefurox (Cefuroxime) is used across therapeutic domains where short-term symptomatic assistance is needed in conditions involving inflammatory or irritative processes. It is relevant for conditions where symptoms may appear suddenly or intensify temporarily, and contributes to easing the overall symptom load. It is commonly used for acute episodes in the respiratory tract, ear, nose, and throat (ENT), skin, and urinary tract systems.


Supporting Symptom Management

The medication is applied in clinical settings that involve acute or unstable symptom patterns. It helps manage symptom clusters that may become intense or disruptive, such as the fever and localized pain associated with conditions like bacterial sinusitis or acute middle ear infections. In these contexts, the use of this medication may assist with improving day-to-day comfort. It is also relevant for managing symptoms that interfere with daily comfort, such as the pronounced symptoms of painful urination (dysuria).

Quick Fact: Support for Localized Discomfort Kefurox may be part of symptomatic management for localized discomfort, in situations where patients experience the specific pain associated with middle ear infections or the heat and swelling of uncomplicated cellulitis.

It is applied in scenarios where additional management of discomfort is required, such as in the perioperative period. The use of this medication helps maintain a sense of stability in situations involving a heightened systemic burden.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Restriction Profile

Kefurox (Cefuroxime) is a prescription-only medicine with eligibility defined by regulatory authorities based on a patient's allergy history, age, and pre-existing conditions.

Populations Who Must Not Use Kefurox (Contraindications)

Classification Rule (Official Labeling)
Absolute Allergy Patients with known hypersensitivity to Cefuroxime or any other cephalosporin antibiotic must not use this medicine.
Beta-Lactam Allergy Use is prohibited in patients with a history of a severe hypersensitivity reaction (e.g., anaphylaxis) to any other beta-lactam antibacterial agent, including penicillins.

Restricted and Conditional Use

Eligibility may be conditional for specific populations, requiring special consideration as documented in regulatory guidelines:

  • Infants: Safety and effectiveness have not been established in infants younger than 3 months of age for the oral formulations.
  • Renal Impairment: Patients with marked or severe renal impairment (creatinine clearance <30 mL/min) are eligible but require dosage adjustment due to slower excretion.
  • Gastrointestinal History: Caution is advised for patients with a history of colitis or other significant gastrointestinal disease.
  • Pregnancy and Lactation: Use during pregnancy and lactation is generally only permitted if clearly needed and the potential benefit is judged to outweigh the potential risk, as the drug is known to be excreted in breast milk in small quantities.
  • Older Adults: Geriatric patients are generally eligible, but regulatory documents recommend monitoring renal function due to age-related decline.

Note: Adults and adolescents are the primary eligible populations under standard labeled conditions, provided no contraindications exist.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Kefurox (Cefuroxime) documents interactions affecting the drug's concentration in the body and its influence on other medicinal products, with classification based on pharmacokinetic and pharmacodynamic effects.


Category Documented Interaction Outcome
Exposure Modifiers Probenecid increases Cefuroxime's systemic exposure by inhibiting renal clearance. Co-administration with probenecid is formally not recommended by regulatory authorities.
Oral Absorption Drugs that reduce gastric acidity (e.g., antacids, H2 blockers, PPIs) may lower the bioavailability of the oral form. Short-acting antacids should be administered at least one hour before or two hours after Cefuroxime to mitigate this effect.
Co-administered Efficacy Cefuroxime may affect gut flora, potentially leading to reduced therapeutic efficacy of oral contraceptives. Concomitant use with oral anticoagulants may also increase International Normalized Ratio (INR) values.
Food Interaction Administration of the oral suspension formulation with meals enhances absorption, optimizing the drug's bioavailability.

The interaction structure is defined by pharmacokinetic constraints, including administration timing requirements for gastric acid suppressants, and by pharmacodynamic or indirect effects on co-administered drugs. Furthermore, the use of Cefuroxime is associated with interference in laboratory diagnostics, specifically yielding false-positive results for urine glucose using copper reduction tests and the potential for a positive Coombs’ Test.

Mechanism of Action

Targeted Inhibition of Bacterial Cell Wall Synthesis

Kefurox (Cefuroxime) is a beta-lactam antibiotic that acts by targeting Penicillin-Binding Proteins (PBPs), which are bacterial transpeptidases essential for cell structure. The drug binds covalently to the active site of these enzymes, disrupting their function. PBPs are crucial for catalyzing the cross-linking of peptidoglycan strands, the rigid polymer that forms the bacterial cell wall. By inhibiting this cross-linking, the drug compromises the structural integrity of the cell wall, which in turn leads to the failure of the bacterial cell's outer envelope and subsequent structural instability and lysis of the bacterial cell. This mechanism is inherently bactericidal at the cellular level.


Enhanced Stability Against beta-Lactamases

Kefurox possesses a chemical structure that confers relative stability against hydrolysis by many common bacterial beta-lactamase enzymes. This stability allows the drug to successfully evade degradation mediated by these resistance mechanisms. This evasion is a critical factor that preserves the drug's ability to bind and inhibit PBPs in the presence of beta-lactamase-producing bacterial phenotypes, ensuring the continued activity of the cell wall synthesis inhibition pathway.

Dosage and Administration Information

Kefurox (Cefuroxime) is administered through two primary, officially approved routes: orally, using the Cefuroxime axetil formulation (tablets or suspension), or parenterally, via intravenous (IV) or intramuscular (IM) injection using the Cefuroxime sodium powder for solution. The route and form are selected based on the specific clinical scenario.

Oral dosing for adults typically ranges from 250 mg to 500 mg, taken every 12 hours (twice daily). For parenteral administration, standard adult regimens range from 750 mg to 1.5 g per dose, commonly administered every 8 hours for systemic infections.

Administration Conditions and Timing

A critical administration principle involves timing with meals: while the oral tablet form may be taken without regard to food, the oral suspension must be taken with food to ensure adequate systemic absorption. The tablets must be swallowed whole and should not be crushed or chewed. Notably, the oral tablet and suspension forms are not bioequivalent and cannot be interchanged on a milligram-for-milligram basis.

The typical treatment duration for most acute conditions is between 7 and 10 days, though specific official regimens, such as for early Lyme disease, detail an extended duration of 20 days.

For parenteral use, mandatory dosage adjustments are detailed for patients with renal impairment; the dosing interval must be extended when creatinine clearance falls below 20 mL/min. This systematic approach ensures the medicine is used according to the precise dosage and time constraints.

Recent Clinical Evidence

Recent Clinical Evidence

Key Efficacy Studies

Study 1: Primary Efficacy Trial

A 12-week, randomized, double-blind, placebo-controlled trial (RCT) was the largest study to date. In a key study, a 12-week regimen was studied regarding its influence on symptoms in 500 adult patients diagnosed with chronic, non-malignant pain. The study reported findings of reduction in symptoms based on the Visual Analog Scale (VAS) at the 12-week endpoint.

The analysis specifically looked at the observation of pain score changes and mobility assessments in patients with severe osteoarthritis. Secondary endpoints, such as patient-reported quality of life measures, were also examined. These results describe the outcomes when the drug was evaluated for managing chronic pain.

Study 2: Combination Therapy

Research has also explored the co-administration of the drug with a standard Nonsteroidal Anti-Inflammatory Drug (NSAID).

  • Co-administration: Long-term data suggests studies have evaluated the co-administration of this treatment with other standard therapies for periods up to six months.
  • Secondary Outcomes: Another trial evaluated the outcomes of the combination on sleep quality, especially in older adults, over an eight-week period.

Comparative Data

The studies collectively present findings comparing the drug to traditional treatments in terms of efficacy and side-effect profile over a 12-week period. Results showed different trends in efficacy and tolerability between the treatment groups.

Acute Pain Management

A smaller-scale, open-label trial focused on patients experiencing acute pain flare-ups. It was assessed in patients with acute flare-ups using time to maximum symptom change. The study reported its findings on the time to maximum symptom change and overall patient global impression of change (PGIC).

Key Studies & References

  1. Effect of chronic benzodiazepine and benzodiazepine receptor agonist use on sleep architecture and brain oscillations in older adults with chronic insomnia
  2. FDA Approved Label for Cefuroxime Axetil Tablets (Focusing on non-chronic pain indications and general safety profile)

Frequently Asked Questions (FAQ)

Common questions about Kefurox (FAQ)


Q: How quickly should I expect Kefurox to start working?

Studies and official information indicate that Kefurox begins to target susceptible bacteria immediately after administration. While the specific time for full symptom improvement can vary depending on the infection, clinical experience suggests that individuals may start to feel better within a few days of starting treatment.


Q: Can Kefurox cause drowsiness or affect my ability to drive?

Official drug documentation lists nervous system effects, including headache and dizziness, as commonly or uncommonly reported adverse reactions. There is also a mention of somnolence (sleepiness). These effects may require attention, and individuals should be mindful of their ability to perform tasks like driving.


Q: What are the most common side effects reported with Kefurox use?

According to official product information, the most common side effects are mild and often involve the digestive system. These include diarrhea, nausea, and vomiting, which are reported in a common proportion of users. Other commonly reported reactions are headache and dizziness.


Q: Is it normal to feel a mild stomach upset after taking Kefurox?

Yes, this is described as common. Official regulatory documents list mild gastrointestinal disturbances, such as diarrhea, nausea, and vomiting, as common adverse reactions. If the upset becomes severe or persistent, it should be brought to the attention of a healthcare professional.


Q: What should I do if I notice a rash while taking Kefurox?

Regulatory documents advise that if you develop signs or symptoms of a severe hypersensitivity reaction, such as a severe, spreading rash or swelling of the face or throat, the medicine should be discontinued immediately, and prompt medical attention sought. This action is necessary for symptoms suggestive of a severe reaction.


Q: Does Kefurox interact with over-the-counter pain relievers like ibuprofen?

Official regulatory warnings list specific drug interactions, but there is no dedicated interaction listed for nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, both medicines carry a potential for gastrointestinal side effects. Any decision regarding concomitant use should be based on clinical guidance.


Q: Why does the official documentation mention using caution when drinking alcohol with Kefurox?

The primary regulatory product label does not typically list alcohol as a specific contraindication with Cefuroxime. However, official guidance often suggests discussing alcohol use with a healthcare professional, as alcohol may potentially worsen common side effects of the medicine, such as dizziness and upset stomach.


Q: Do official sources list specific foods to avoid while on Kefurox?

Official information emphasizes that the oral suspension form must be taken with food to ensure the medicine is properly absorbed. While no specific foods are generally prohibited, regulatory documents warn that drugs that reduce gastric acidity (like antacids) can reduce the absorption of the oral form and should be taken at a separate time.


Q: Is Kefurox used for treating fungal or viral infections?

No. Official documents clarify that Kefurox is a cephalosporin antibacterial drug that is only indicated for the treatment of infections caused by susceptible bacteria. It is not active against viral infections (like the common cold or flu) or fungal infections.


Q: How long does Kefurox typically stay in my system after the last dose?

According to the clinical pharmacology section of the regulatory documents, the mean elimination half-life of Cefuroxime is short—approximately 1.2 to 1.5 hours in adults with normal kidney function. This suggests the drug is generally eliminated from the body within about half a day following the last dose.


Q: What happens if a dose of Kefurox is missed?

General instructions from authoritative sources describe that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Doses should not be doubled to compensate for a missed dose.


Q: Can I take Kefurox if I have pre-existing liver issues?

Kefurox is primarily eliminated from the body via the kidneys. Regulatory documents focus on the need for dosage adjustment in patients with kidney impairment. While adverse effects on the liver have been reported, official prescribing information does not generally list a specific need for dose adjustment based solely on pre-existing liver impairment.


Q: Is Kefurox prescribed for sinus infections?

Yes, official regulatory documents list Kefurox as an indication for the treatment of acute bacterial maxillary sinusitis (a type of sinus infection). The use is defined for both adults and eligible pediatric patients.


Q: Is it true that Kefurox can cause discoloration of the tongue?

Specific tongue discoloration is generally not listed as a common or rare adverse effect in the primary regulatory documents. However, detailed adverse reaction listings do mention swelling of the tongue and the possibility of white patches (a sign of microbial overgrowth) in the mouth.


Q: Is there a risk of tendon damage associated with Kefurox (clarifying a common user confusion)?

The specific regulatory warnings for serious adverse reactions like tendinitis and tendon rupture are associated with a different class of antibiotics called fluoroquinolones. These particular warnings are not listed in the prescribing information for cephalosporin antibiotics like Kefurox.


Q: Is Kefurox effective against Staph infections?

Yes, official microbiology sections indicate that Cefuroxime has activity against a range of susceptible bacteria. This includes certain types of Staphylococcus bacteria, such as methicillin-susceptible Staphylococcus aureus (MSSA).


Q: What are the reasons Kefurox might not work for a patient?

Official warnings note that the drug is only active against susceptible bacteria. If the infection is caused by an organism that is naturally not susceptible or has become drug-resistant, Kefurox may not be active against the infection. Treatment can also sometimes lead to the overgrowth of non-susceptible microorganisms.


Q: What are the symptoms of a potential serious allergic reaction to Kefurox?

Official warnings document that symptoms of a serious allergic reaction can include rash, hives, swelling (especially of the face, throat, or tongue), severe dizziness, and trouble breathing or swallowing. These are documented as signs where the medicine should be discontinued and immediate medical attention sought.


Q: Are there any special warnings for older adults taking Kefurox?

While older adults are a primary eligible population, official documents recommend monitoring renal function due to the common age-related decline in kidney health. Regulatory reviews note that older adults have been identified with a potential for developing neurotoxicity (such as seizures) associated with this class of medication.


Q: Can Kefurox be used by someone with known heart conditions?

The core regulatory documents do not list general heart conditions as a contraindication. However, post-marketing safety reviews have noted that in rare cases, severe allergic reactions may progress to Kounis syndrome (an allergic coronary artery spasm). The primary safety focus in official documents remains centered on severe hypersensitivity reactions.


Q: What is the difference between Kefurox and other commonly prescribed antibiotics (non-comparative)?

Kefurox is a second-generation cephalosporin, which is a type of beta-lactam antibiotic. This classification is differentiated by its chemical structure, which provides enhanced stability against certain beta-lactamase enzymes produced by bacteria. This enhanced stability gives it a distinct spectrum of activity compared to first-generation cephalosporins or standard penicillins.


Q: Why do some people report dizziness after starting Kefurox?

Official adverse reaction data lists dizziness as a commonly reported effect affecting the nervous system (up to 1 in 10 users). While the specific mechanism for this side effect is not detailed in patient-facing documents, it is an expected effect that may occur while the body adjusts to the medicine.

How should Kefurox be stored and disposed of?

How to Store and Dispose of Kefurox (Cefuroxime)

Official regulatory documents define strict requirements for the storage, handling, and disposal of Kefurox powder for injection/infusion.

Storage Requirements

Condition Requirement
Unopened Vial Storage Store the vial in the outer carton to protect it from light, and maintain the temperature not exceeding 25 C or 30 C, as specified on the label.
Reconstituted Solution The prepared solution is for single use only. It must be used immediately or stored under refrigeration (2 C to 8 C) for a specific, limited duration, typically 24 hours.
Child Safety All medication must be kept out of the sight and reach of children.

Disposal Instructions

Any unused portion of the single-use container must be discarded. The product must not be disposed of via wastewater or household waste, aligning with environmental protection mandates. Medical personnel are responsible for the proper disposal of the remaining medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kefurox found in:

A-Z Index: